findmyKOL

Albert Khouri, MD

Enriched profile

Professor of Ophthalmology, Director of the Glaucoma Division, and Program Director of the Ophthalmology Residency · Rutgers New Jersey Medical School

ORCIDNPI
Region🇺🇸 Newark, NJ · Northeast · United StatesSpecialtyOphthalmologyFocusGlaucoma
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Albert Khouri is Professor of Ophthalmology, Director of the Glaucoma Division, and Program Director of the Ophthalmology Residency at Rutgers New Jersey Medical School. OpenAlex indexes 285 publications with 1,801 citations (h-index 21); ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Albert S. Khouri, MD, is Professor of Ophthalmology, Director of the Glaucoma Division, and Program Director of the Ophthalmology Residency at Rutgers New Jersey Medical School, Department of Ophthalmology & Visual Science. The public record shows 285 publications with 1,801 citations (h-index 21), centered on Glaucoma. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 15 companies.

  • Most recent indexed publication: 2024 · Journal of current glaucoma practice
  • Top research focus: Glaucoma
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 15 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Glaucoma1 trialComa1 trial

Research focus

OpenAlex concept fingerprint
Glaucoma

Drugs & molecules

across trials, industry payments and publications
Durystageneric · BimatoprostClinical trialsIndustry payments99PublicationsVyzultageneric · Latanoprostene bunodClinical trialsIndustry payments90PublicationsRocklatangeneric · Latanoprost / netarsudilClinical trialsIndustry payments32Publications

Works with

trial sponsors and companies reporting payments
Bausch & Lomb Americas Inc.Clinical trialsIndustry payments90Abbvie Inc.Clinical trialsIndustry payments57Allergan, Inc.Clinical trialsIndustry payments56

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
285publications

Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.

1,801citations

Total citations across indexed works.

21h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
15companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

15 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    88.7%
    Prostaglandin Analog28.8%
    Latanoprost59%Lumigan31%Travoprost6%Bimatoprost1%Zioptan1%Tafluprost1%Travatan Z1%
    Part D<11 patients
    Carbonic Anhydrase Inhibitor28.4%
    Dorzolamide-Timolol56%Dorzolamide Hcl19%Simbrinza14%Acetazolamide4%Brinzolamide4%Acetazolamide Er1%Azopt1%
    Part D<11 patients
  • Cardiovascular

    6.9%
    Beta blocker6.9%
    Timolol Maleate100%
    Part D112 patients
  • Cancer & immunology

    1.6%
    Calcineurin inhibitor1.6%
    Restasis77%Cyclosporine24%
    Part D<11 patients
5 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/albert-khouri-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/albert-khouri-a0a4a58b

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com

Mentions by others

where others cite or feature them
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com
  • LinkedIn

    LinkedIn: "Albert Khouri - Professor of Ophthalmology, Glaucoma Director, Residency Director at Rutgers New Jersey Medical School"

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    American University of Beirut, Lebanon

    1992
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →njms-web.njms.rutgers.edu
  • BS

    American University of Beirut, School of Arts & Sciences, Lebanon

    1988
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →njms-web.njms.rutgers.edu
  • Board Certified

    Ophthalmology (American Board of Ophthalmology)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com

Editorial & leadership roles

journal and society appointments
  • Program Director

    Ophthalmology Residency, Rutgers New Jersey Medical School

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →njms-web.njms.rutgers.edu
  • Director

    Glaucoma Division, Rutgers New Jersey Medical School

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →njms-web.njms.rutgers.edu
  • Medical Director

    Ophthalmology Telemedicine, Rutgers New Jersey Medical School

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →njms-web.njms.rutgers.edu
1 more role behind the reveal.Reveal →

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • University Hospital

    Newark, NJ (hospital affiliation)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →njms-web.njms.rutgers.edu

Media & interviews

press, podcasts and appearances
  • Guest

    "Telemedicine in Glaucoma" episode (S2E9), Eye Tea Ophthalmology Podcast, with Drs. Ben Szirth and Natasha Kolomeyer

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eyetea.club

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.